XML 33 R22.htm IDEA: XBRL DOCUMENT v3.25.3
Segment Reporting (Tables)
 9 Months Ended
Sep. 30, 2025
Segment Reporting [Abstract]  
Schedule of Reportable Segment Profit and Loss, Including Significant Expense Categories

The following table presents reportable segment profit and loss, including significant expense categories, attributable to our reportable segment for the three and nine months ended September 30, 2025 and 2024:

 

   2025   2024   2025   2024 
  

Three Months Ended

September 30,

  

Nine Months Ended

September 30,

 
   2025   2024   2025   2024 
Preclinical, clinical trial and other costs  $1,204,017   $1,850,812   $4,543,279   $4,143,813 
Research and development personnel expense(1)   457,629    436,713    1,153,412    1,412,881 
General and administrative personnel expense(2)   855,089    493,144    2,157,979    1,457,941 
Administrative and facilities expense(3)   972,108    644,184    2,431,946    2,301,840 
Other income, net   (52,270)   (40,150)   (81,720)   (195,065)
Total  $3,436,573   $3,384,703   $10,204,896   $9,121,410 

 

(1) Research and development personnel costs include employee stock-based compensation expense of $110,239 and $54,018 for the three months ended September 30, 2025 and 2024, respectively, and $165,572 and $130,722 for the nine months ended September 30, 2025 and 2024, respectively.
   
(2) General and administrative personnel costs include employee stock-based compensation expense of $192,808 and $53,725 for the three months ended September 30, 2025 and 2024, respectively, and $438,118 and $132,905 for the nine months ended September 30, 2025 and 2024, respectively, and are net of reimbursements received from CorLyst, LLC.
   
(3) Administrative & facilities expense primarily consists of facilities expenses, office expenses, legal costs, insurance, consulting, travel, and other administrative costs.